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VTE,	 particularly	 provoked	PE.	 The	 association	 displayed	 a	 threshold	 pattern	 and	
suggested	a	protective	effect	of	an	n-	3	PUFA	intake	≥4.7	g/week.
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Contemporary	 data	 have	 shown	 that	 the	 incidence	 of	 VTE	 has	 re-
mained	 stable	 or	 increased	 slightly	 over	 the	 past	 decades,6,7 which 





and	 is	 now	 implemented	 in	 dietary	 guidelines	 worldwide.12-14 The 
beneficial	effects	are	largely	attributed	to	the	essential	long-	chained	

















assessment	 and	 data	 handling.	 First,	 the	 content	 of	 n-	3	 PUFAs	 in	
fatty	fish	can	be	up	to	seven-	to	eightfold	higher	than	in	 lean	fish,	
and	dietary	 supplements	comprise	even	higher	n-	3	PUFA	concen-
trations.26,27	 It	 is	 therefore	possible	 to	have	a	high	 intake	of	 (lean)	






























has	 been	 published	 elsewhere.29	 Briefly,	 the	 entire	 (Tromsø	 4)	 or	
parts	(Tromsø	6)	of	the	adult	population	were	invited	to	participate,	
and	 the	 attendance	 rates	 ranged	 from	 66%	 in	 Tromsø	 6%-	77%	 in	
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(in	cm)	and	weight	(in	kg)	were	measured	with	participants	dressed	
in	 light	 clothes	with	 no	 shoes,	 and	 BMI	was	 calculated	 as	weight	
divided	by	 the	 square	of	height	 (in	m,	kg/m2).	Blood	pressure	and	
serum	lipid	concentrations	were	assessed	according	to	procedures	
described	 previously.30	 Information	 on	 fish	 intake,	 use	 of	 dietary	
supplements,	education,	current	smoking,	diabetes,	and	prior	CVD	
(comprising	myocardial	infarction,	angina	pectoris,	and	stroke)	were	
based	 on	 self-	administered	 questionnaires.	 Information	 on	 cancer	
history	was	obtained	from	the	Norwegian	Cancer	Registry.
2.3 | Assessment and validation of marine n- 3 
PUFA and fish intake
Information	on	dietary	intake	was	obtained	by	self-	administered	ques-
tionnaires.31	In	Tromsø	4,	participants	aged	<70	years	were	asked	to	
report	 how	 frequently	 they	 consumed	 lean	 and	 fat	 fish	 for	 dinner	
and	how	often	they	used	fish	as	spread	on	bread	(never,	<1,	1/week,	
2-	3/week,	4-	5/week,	or	daily).	Participants	 aged	≥70	years	 received	
a	 similar	 questionnaire,	 but	with	 fewer	 options	 (never,	 <1/week,	 1/
week	or	 ≥2/week).	 These	 assessments	were	 repeated	 in	 Tromsø	6,	
however,	 the	 frequency	 options	 differed	 slightly	 from	 those	 in	 the	
Tromsø	 4	 questionnaire	 (0-	1/month,	 2-	3/month,	 1-	3/week,	 4-	6/
week,	or	1-	2/day.	 In	both	 surveys,	 the	participants	were	also	asked	












of	 fat	 and	 lean	 fish,	 fish	 as	 bread	 spread	 and	 fish	 oil	 supplements.	








Q1 (n = 6970) Q2 (n = 7012) Q3 (n = 6967) Q4 (n = 6913)
Quartile	range,	g/wk <4.7 4.7-	13.4 >13.4-	29.1 >29.1
Age,	y 41	(12) 47	(14) 49	(14) 56	(14)
Sex,	male 47.1	(3282) 50.6	(3546) 40.8	(3539) 46.4	(3210)








1.45	(0.38) 1.48	(0.40) 1.50	(0.42) 1.56	(0.44)
Serum	triglycerides,	
mmol/L
1.54	(1.01) 1.55	(1.00) 1.52	(1.00) 1.46	(0.89)
Systolic	blood	
pressure,	mmHg
130	(17) 133	(20) 133	(20) 138	(23)
Diastolic blood 
pressure,	mmHg
76	(11) 77	(11) 77	(11) 78	(11)
Current	smoking 38.0	(2640) 31.6	(2210) 27.6	(1916) 22.4	(1541)
Diabetes 1.6	(108) 2.3	(158) 2.6	(181) 3.5	(241)
History	of	CVD 3.2	(221) 5.7	(398) 6.8	(471) 10.3	(700)
History	of	cancer 1.7	(116) 2.7	(192) 3.5	(243) 5.9	(410)
Higher	educationb 34.4	(2391) 36.0	(2511) 40.0	(2775) 38.0	(2615)
Values	are	mean	(±SD)	or	percentage	(count).
BMI,	body	mass	index;	CVD,	cardiovascular	disease	(angina	pectoris,	stroke,	myocardial	infarction);	
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and	DHA)	in	the	cholesterol-	ester	fraction	was	measured	in	a	sub-










if	 all	 of	 the	 following	 criteria	were	 present:	 signs	 and	 symptoms	













immobilization	 (bed	 rest	 ≥3	days,	 confinement	 to	wheelchair,	 long	
distance	travel	≥4	hours	within	the	last	14	days),	or	other	provoking	
factors	specified	 in	 the	medical	 record	 (eg,	 intravascular	catheter).	
The	remaining	cases	were	categorized	unprovoked.	The	events	were	












ity	 of	 Tromsø	 (n	=	3525)	 during	 follow-	up	were	 censored	 at	 these	
respective	time	points.
Statistical	 analyses	 were	 performed	 with	 STATA	 ver-
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TABLE  3  IRs	and	HRs	with	95%	CIs	for	VTE,	PE,	and	DVT,	overall	and	stratified	by	the	presence	of	provoking	factors,	across	quartiles	of	
weekly	intake	of	marine	n-	3	PUFAs	in	the	Tromsø	Studya
n- 3 PUFA intake (g/wk) Person- years VTE events
Crude IR  
(95% CI)b
HR model 1  
(95% CI)c P value
HR model 2  
(95% CI)d P value
Total	VTE
Q1	<	4.7 96 809 120 1.24	(1.04-	1.48) 1.00 0.12 1.00 0.13
Q2	4.7-	13.4 88 864 120 1.35	(1.13-	1.61) 0.75	(0.58-	0.96) 0.74	(0.57-	0.96)
Q3	>	13.4-	29.1 81 104 129 1.59	(1.34-	1.89) 0.77	(0.6-	1) 0.77	(0.59-	0.99)
Q4	>	29.1 71	711 172 2.40	(2.07-	2.79) 0.78	(0.61-	1) 0.78	(0.61-	1)
Unprovoked	VTE
Q1	<	4.7 96 809 46 0.48	(0.36-	0.63) 1.00 0.81 1.00 0.82
Q2	4.7-	13.4 88 864 49 0.55	(0.42-	0.73) 0.81	(0.54-	1.21) 0.81	(0.54-	1.21)
Q3	>	13.4-	29.1 81 104 59 0.73	(0.56-	0.94) 0.94	(0.64-	1.4) 0.94	(0.63-	1.40)
Q4	>	29.1 71	711 73 1.02	(0.81-	1.28) 0.89	(0.60-	1.31) 0.89	(0.6-	1.31)
Provoked	VTE
Q1	<	4.7 96 809 74 0.76	(0.6-	0.96) 1.00 0.07 1.00 0.07
Q2	4.7-	13.4 88 864 71 0.89	(0.63-	1.01) 0.71	(0.51-	0.99) 0.70	(0.51-	0.98)
Q3	>	13.4-	29.1 81 104 69 0.85	(0.67-	1.08) 0.66	(0.47-	0.93) 0.65	(0.47-	0.91)
Q4	>	29.1 71	711 99 1.38	(1.13-	1.68) 0.72	(0.52-	0.98) 0.72	(0.52-	0.98)
Total	DVT
Q1	<	4.7 96 809 60 0.62	(0.48-	0.8) 1.00 0.51 1.00 0.50
Q2	4.7-	13.4 88 864 74 0.83	(0.66-	1.05) 0.95	(0.68-	1.35) 0.95	(0.67-	1.34)
Q3	>	13.4-	29.1 81 104 81 1.01	(0.81-	1.26) 1.02	(0.72-	1.43) 1.01	(0.72-	1.42)
Q4	>	29.1 71	711 90 1.26	(1.26-	1.54) 0.88	(0.62-	1.24) 0.87	(0.62-	1.23)
Unprovoked	DVT
Q1	<	4.7 96 809 23 0.24	(0.16-	0.36) 1.00 0.87 1.00 0.87
Q2	4.7-	13.4 88 864 26 0.29	(0.20-	0.43) 0.88	(0.5-	1.55) 0.88	(0.50-	1.54)
Q3	>	13.4-	29.1 81 104 35 0.43	(0.31-	0.6) 1.15	(0.67-	1.97) 1.14	(0.67-	1.96)
Q4	>	29.1 71	711 38 0.53	(0.39-	0.73) 0.96	(0.56-	1.66) 0.96	(0.56-	1.66)
Provoked	DVT
Q1	<	4.7 96 809 37 0.38	(0.28-	0.53) 1.00 0.32 1.00 0.31
Q2	4.7-	13.4 88 864 48 0.54	(0.41-	0.72) 1.00	(0.65-	1.54) 1.00	(0.65-	1.54)
Q3	>	13.4-	29.1 81 104 46 0.57	(0.42-	0.76) 0.93	(0.6-	1.45) 0.93	(0.60-	1.44)
Q4	>	29.1 71	711 52 0.73	(0.55-	0.95) 0.82	(0.53-	1.28) 0.82	(0.53-	1.28)
Total	PE
Q1	<	4.7 96 809 60 0.62	(0.48-	0.8) 1.00 0.11 1.00 0.13
Q2	4.7-	13.4 88 864 46 0.52	(0.39-	0.69) 0.55	(0.37-	0.81) 0.54	(0.37-	0.8)
Q3	>	13.4-	29.1 81 104 47 0.58	(0.44-	0.77) 0.53	(0.36-	0.79) 0.53	(0.36-	0.78)
Q4	>	29.1 71	711 82 1.14	(0.92-	1.42) 0.68	(0.47-	0.96) 0.69	(0.48-	0.98)
Unprovoked	PE
Q1	<	4.7 96 809 23 0.24	(0.16-	0.36) 1.00 0.59 1.00 0.6
Q2	4.7-	13.4 88 864 23 0.26	(0.17-	0.39) 0.74	(0.41-	1.33) 0.74	(0.41-	1.33)
Q3	>	13.4-	29.1 81 104 24 0.30	(0.20.0.44) 0.75	(0.42-	1.34) 0.74	(0.42-	1.33)
Q4	>	29.1 71	711 35 0.49	(0.35-	0.68) 0.81	(0.46-	1.41) 0.81	(0.47-	1.42)
(Continues)
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(The	 R	 Foundation	 for	 Statistical	 Computing,	 Vienna,	 Austria).	
Demographics	and	clinical	characteristics	across	quartiles	of	n-	3	
PUFA	and	fish	intake	were	reported	as	means	with	SD.	Crude	in-
cidence	 rates	 (IRs)	 for	VTE	were	calculated	across	quartiles	and	
expressed	as	number	of	events	per	1000	person-	years.	Cox	pro-
portional	hazards	regression	models	with	age	as	time	scale	were	






In	 addition	 to	 analyzing	 across	 quartiles	 of	 n-	PUFA	 intake,	 Cox	
analyses	with	a	restricted	cubic	spline	with	four	knots	fitted	to	the	
n-	PUFA	intake	values	were	performed	and	plotted.
The	 proportional	 hazards	 assumption	 was	 evaluated	 and	 con-
firmed	based	on	Schoenfeld	residuals	using	a	global	test.	Statistical	




















































n- 3 PUFA intake (g/wk) Person- years VTE events
Crude IR  
(95% CI)b
HR model 1  
(95% CI)c P value
HR model 2  
(95% CI)d P value
Provoked	PE
Q1	<	4.7 96 809 37 0.38	(0.28-	0.53) 1.00 0.10 1.00 0.11
Q2	4.7-	13.4 88 864 23 0.26	(0.17-	0.39) 0.43	(0.25-	0.73) 0.42	(0.25-	0.72)
Q3	>	13.4-	29.1 81 104 23 0.28	(0.19-	0.43) 0.41	(0.24-	0.69) 0.40	(0.23-	0.68)















week.	Again,	 the	 largest	 effect	 sizes	were	 observed	 in	 relation	 to	









explored	 across	 quartiles	 of	 weekly	 fish	 intake,	 regardless	 of	 n-	3	
PUFA	content,	no	significant	associations	were	observed	(Table	S5).




those who were excluded.
4  | DISCUSSION
In	 the	 present	 study,	 we	 investigated	 the	 association	 between	
self-	reported	 intake	 of	marine	 n-	3	 PUFAs	 validated	 against	meas-









Previous	 reports	 on	 the	 association	 between	 n-	3	 PUFAs	 or	
fish	intake	and	the	risk	of	VTE	have	been	conflicting,	and	a	recent	
systematic	 review	 concluded	 that	 a	 risk	 modifying	 effect	 of	 fish	
consumption	has	meager	support	 in	 the	 literature.32	However,	 the	
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was	updated	 for	 those	participating	 in	both	surveys.	This	 resulted	
in	a	shorter	time	interval	between	assessment	of	exposure	and	out-
come	for	a	part	of	the	study	population	(27%).	Still,	sensitivity	anal-
yses	with	observation	 time	 further	 restricted	 to	maximum	5	years	








risk	 of	 VTE.	 Similarly,	 studies	 reporting	 separate	 analyses	 for	 in-
take	of	lean	and	fatty	fish	(ie,	low	and	high	n-	3	PUFA	content)	have	
generally	found	largest	effect	sizes	in	relation	to	fatty	fish	and	fish	
n- 3 PUFA intake Person- years VTE events Crude IR (95% CI)b HR (95% CI)c
Total	VTE
Q1d 96 809 120 1.24	(1.04-	1.48) 1
Q2-	Q4e 241	678 421 1.74	(1.58-	1.92) 0.76	(0.62-	0.94)
Unprovoked	VTE
Q1d 96 809 46 0.48	(0.36-	0.63) 1
Q2-	Q4e 241	678 181 0.75	(0.65-	0.87) 0.88	(0.63-	1.23)
Provoked	VTE
Q1d 96 809 74 0.76	(0.61-	0.96) 1
Q2-	4e 241	678 239 0.99	(0.87-	1.12) 0.69	(0.53-	0.91)
Total	DVT
Q1d 96 809 60 0.62	(0.48-	0.8) 1
Q2-	Q4e 241	678 245 1.02	(0.90-	1.15) 0.95	(0.71-	1.27)
Unprovoked	DVT
Q1d 96 809 23 0.24	(0.16-	0.36) 1
Q2-	Q4e 241	678 99 0.41	(0.34-	0.5) 0.99	(0.62-	1.59)
Provoked	DVT
Q1d 96 809 37 0.38	(0.28-	0.53) 1
Q2-	Q4e 241	678 146 0.60	(0.51-	0.71) 0.92	(0.63-	1.33)
Total	PE
Q1d 96 809 60 0.62	(0.48-	0.8) 1
Q2-	Q4e 241	678 175 0.72	(0.62-	0.84) 0.59	(0.43-	0.80)
Unprovoked	PE
Q1d 96 809 23 0.24	(0.16-	0.36) 1
Q2-	Q4e 241	678 82 0.34	(0.27-	0.42) 0.77	(0.47-	1.24)
Provoked	PE
Q1d 96 809 37 0.38	(0.28-	0.53) 1
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oil	supplements.21,24	This	suggests	that	a	high-	fish	diet	may	not	be	





















acteristics	 are	 equal,	 it	 follows	 that	 a	 given	provoking	 factor	more	
readily	exceeds	 the	 threshold	 for	 thrombus	 formation	under	 inad-














for	 changes	 in	 dietary	 habits	 during	 follow-	up	 with	 repeated	
assessments	 and	 including	 n-	3	 PUFA	 intake	 as	 a	 time-	varying	
variable	 in	our	analyses.	However,	 some	 limitations	of	 the	study	
merit consideration. There were substantial exclusions due to 
incomplete	 questionnaires,	 and	 the	 included	 participants	 were	
younger	and	healthier	compared	with	those	who	were	excluded.	
This	 influences	 the	 generalizability	 of	 the	 study	 population,	 but	
the	study	still	addresses	the	principal	association	between	intake	
of	n-	3	PUFAs	and	the	risk	of	VTE.	However,	several	factors	may	
influence	 the	precision	of	our	 risk	estimates.	The	 reproducibility	
of	self-	reported	fish	intake	in	the	Tromsø	study	has	been	reported	
to	 be	moderate	 (Spearman	 correlation	 coefficient =	0.41-	0.56),41 
and	 in	 general,	 dietary	 questionnaires	 may	 only	 reflect	 20%	 of	
n-	3	PUFAs	levels	measured	in	erythrocytes.42	However,	these	are	
misclassifications	unrelated	to	the	outcome,	which	would	lead	to	
underestimated	 risk	 estimates.	 Additionally,	 although	 we	 reas-
sessed	exposure	during	follow-	up,	the	median	duration	of	the	ob-
servation	periods	was	still	 relatively	 long	 in	our	study	 (12	years).	
As	 confirmed	 by	 the	 sensitivity	 analyses	with	maximum	 5	years	




models	were	 tested.	Finally,	 there	were	 slight	differences	 in	 the	
questionnaires	used	the	fourth	and	the	sixth	survey	of	the	Tromsø	
Study.	 However,	 serum	 triglyceride	 concentrations	 predicatively	
decreased	 with	 increasing	 n-	3	 PUFA	 intake,43 and there was a 
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